Ultragenyx Pharmaceutical Inc. Stock
There is no change in the price for Ultragenyx Pharmaceutical Inc. today.
The stock is an absolute favorite of our community with 26 Buy predictions and no Sell predictions.
Based on the current price of 23.14 € the target price of 50 € shows a potential of 116.08% for Ultragenyx Pharmaceutical Inc. which would more than double the current price.
Pros and Cons of Ultragenyx Pharmaceutical Inc. in the next few years
Pros
?
C******** o* t** e**********
?
B****
?
W********* I********* f** t** n*** y****
Cons
?
G***** c******* t* c**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Ultragenyx Pharmaceutical Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. | 0.000% | 2.224% | -22.181% | -1.795% | 36.786% | -30.364% | -70.538% |
| Ligand Pharmaceuticals | 1.560% | -4.580% | -9.420% | 96.850% | 50.602% | 296.825% | 166.923% |
| United Therapeutics | -0.720% | -0.800% | -6.885% | 72.317% | 4.447% | 105.384% | 155.029% |
| Ionis Pharmaceuticals Inc. | 0.830% | 0.524% | -5.919% | 36.364% | -29.370% | 32.414% | 47.420% |
Comments
Ultragenyx Pharmaceutical (RARE) had its "buy" rating reaffirmed by HC Wainwright. They now have a $50.00 price target on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Wells Fargo & Company from $47.00 to $45.00. They now have an "overweight" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
Ultragenyx Pharmaceutical (RARE) had its price target lowered by Guggenheim from $43.00 to $35.00. They now have a "buy" rating on the stock.
Show more
Ratings data for RARE provided by MarketBeat
News
Ultragenyx Pharmaceutical Q2 Earnings Call Highlights
Key Points
- Interested in Ultragenyx Pharmaceutical Inc.? Here are five stocks we like better.
- Ultragenyx reported record Q2 revenue of $214 million, led by Crysvita’s $156 million contribution
What to Know About This Fund's $5.4 Million Ultragenyx Purchase as Shares Slip 30% in One Year
On May 14, 2026, Krensavage Asset Management disclosed it bought 241,245 shares of Ultragenyx Pharmaceutical (NASDAQ:RARE), an estimated $5.43 million trade based on quarterly average pricing.
